RoslinCT
Edinburgh, UK · Hopkinton, MA
Program data pending ClinicalTrials.gov matching
· Last scored 2026-04-29
79.8
Signal Score
✓ FDA Inspections (1)
○ Clinical Trials
○ SEC Filings
○ Press
○ EMA GMP
✓ MHRA GMP (1)
Quick Facts: RoslinCT
- Signal Score
- 79.8/100 (as of 2026-04-29)
- Quality Compliance
- 97.8/100
- Headquarters
- Edinburgh, UK · Hopkinton, MA
- Modalities
- CAR-T, Cell Therapy, iPSC, Gene Editing
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About RoslinCT
Merged with Lykan Bioscience.
Signal Score & Pillar Breakdown
Quality Compliance
97.8
FDA Inspections1 on record
Warning Letters0
Last InspectionVoluntary Action Indicated (VAI) (2025-01-21)
MHRA GMP Certificates1 on record
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesCAR-T, Cell Therapy, iPSC, Gene Editing
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
68.0
2 manufacturing sites
Broad modality coverage (4 modalities)
Sites: Edinburgh, UK, Hopkinton, MA
Source: SEC EDGAR, press monitoring, company profiles
2 manufacturing sites
StatusAvailable
2 manufacturing sites
Broad modality coverage (4 modalities)
Sites: Edinburgh, UK, Hopkinton, MA
2 manufacturing sites
Broad modality coverage (4 modalities)
RoslinCT FDA Inspection History
2025-01
NAI
VAI
OAI
| Date | Site | Type | Observations | Classification |
|---|---|---|---|---|
| 2025-01-21 | Edinburgh | Human Cellular, Tissue, and Gene Therapies | Yes | Voluntary Action Indicated (VAI) |
Source: FDA Data Dashboard · Retrieved Jul 04, 2026
RoslinCT MHRA GMP Compliance 1 certificates
2021-07
Compliant
Non-Compliant
| Certificate | Site | City / Postcode | Inspection Date | Status |
|---|---|---|---|---|
| UK MIA(IMP) 45803 Insp IMP 45803/4883575-0018[I] | ROSLINCT INSTITUTE FOR REGENERATION AND REPAIR NORTH | EDINBURGH EH16 4UU | 2021-07-27 | COMPLIANT |
Source: MHRA GMDP Database · Retrieved Jul 04, 2026
Frequently Asked Questions About RoslinCT
How many FDA inspections does RoslinCT have on record?
CDMO Signal tracks 1 FDA inspection for RoslinCT, sourced from the FDA inspection database. See the full inspection history above.
Has RoslinCT received an FDA warning letter?
CDMO Signal has no FDA warning letters on record for RoslinCT.
Does RoslinCT hold EMA or MHRA GMP certificates?
CDMO Signal tracks 1 MHRA GMP certificate for RoslinCT.
What is RoslinCT's CDMO Signal Score?
RoslinCT has a Signal Score of 80/100, based on quality, operations, financial stability, and capacity data.
Evaluating RoslinCT for a manufacturing program?
Use the free AI matchmaker to compare RoslinCT against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 91.7
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
GenScript
Piscataway, NJ
Signal Score: 65.5
CAR-T, Cell Therapy, Gene Editing
CTMC
Houston, TX
Signal Score: 63.0
CAR-T, Cell Therapy, Gene Editing
Poseida Therapeutics (CDMO)
San Diego, CA
Signal Score: 58.7
CAR-T, Cell Therapy, Gene Editing
Rose BioSolutions
Rockville, MD
Plasmid DNA, AAV, Lentiviral, Adenoviral, CAR-T, Cell Therapy, Gene Editing, Cell Solutions / Starting Materials